Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: Induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone

Endocrine Practice

Volumn 13, Issue 6, 2007, Pages 601-608

  Bahtiyar, Gül ^a   Weiss, Karolina ^a   Sacerdote, Alan S ^a  

^a WOODHULL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CORTODOXONE; ENDOCRINE DISRUPTOR; ESTRADIOL; ESTRONE; FOLLITROPIN; HYDROXYPROGESTERONE; LUTEINIZING HORMONE; METFORMIN; NEUROLEPTIC AGENT; PRASTERONE; ROSIGLITAZONE; TESTOSTERONE; VALPROIC ACID;

ADOLESCENT; ADRENAL GLAND; ADULT; AGED; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RADIOIMMUNOASSAY;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADRENAL GLANDS; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CORTODOXONE; DEHYDROEPIANDROSTERONE; ENDOCRINE DISRUPTORS; ESTRADIOL; ESTRONE; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPERANDROGENISM; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LUTEINIZING HORMONE; MALE; METFORMIN; MIDDLE AGED; RADIOIMMUNOASSAY; TESTOSTERONE; THIAZOLIDINEDIONES; VALPROIC ACID;

EID: 38449094731     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.13.6.601     Document Type: Article

References (30)

1. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66:504-514.
2. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329:1383-1388.
3. Joffe H, Cohen LS, Suppes T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59:1078-1086.
4. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC. Endocrine and metabolic effects of rosiglitazone in overweight women with PCOS: a randomized placebo-controlled study. Hum Reprod. 2006;6:1400-1407.
5. Tan S, Hahn S, Janssen OE. Insulin resistance syndrome and polycystic ovary syndrome: implications for diagnosis and treatment. Panminerva Med. 2005;47:211-217.
6. Speiser PW, Serrat J, New MI, Gertner JM. Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 1992;75:1421-1424.
7. Saygili F, Oge A, Yilmaz C. Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between serum leptin levels and chronic hyperinsulinemia. Horm Res. 2005;63:270-274.
8. Paula FJ, Gouveia LM, Paccola GM, Piccinato CE, Moreira AC, Foss MC. Androgen-related effects on peripheral glucose metabolism in women with congenital adrenal hyperplasia. Horm Metab Res. 1994;26:552-556.
9. Rager KM, Omar HA. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN. Scientific World Journal. 2006;24:116-121.
10. Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab. 2006;91:2-6.
11. McKenna TJ, Cunningham SK. Adrenal androgen production in polycystic ovary syndrome. Eur J Endocrinol. 1995;133:383-389.
12. Mauras N, Welch S, Rini A, Haymond MW. Ovarian hyperandrogenism is associated with insulin resistance to both peripheral carbohydrate and whole-body protein metabolism in postpubertal young females: a metabolic study. J Clin Endocrinol Metab. 1998;83:1900-1905.
13. Sacerdote A, Vergara R, Carnegie B. Do all patients with NIDDM have late-onset congenital adrenal hyperplasia? In: Program and abstracts of the 76th Annual Meeting of The Endocrine Society; June 15-18, 1994; Anaheim, CA. Abstract 350.
14. Sacerdote AS. Adrenal androgens and NIDDM. Diabetes Care. 1995;18:278-279.
15. Osehobo E, Shaw I, Sacerdote A. Do insulin sensitizers repair the gene defects in non-classical congenital adrenal hyperplasia? In: Program and abstracts of the 82nd Annual Meeting of The Endocrine Society; June 21-24, 2000; Toronto, Canada. Abstract 547.
16. Sacerdote A. Weight-dependent expression of non-classical aldosterone synthase deficiency. In: Program and abstracts of the 84th Annual Meeting of The Endocrine Society; June 19-22, 2002; San Francisco, CA. Abstract 599.
17. Sacerdote AS, Sanchez JU, Ogbeide O, Slabodkina L. Modification of expression of non-classical congenital adrenal hyperplasia by rosiglitazone. In: Program and abstracts of the 85th Annual Meeting of The Endocrine Society; June 19-22, 2003; Philadelphia, PA. Abstract 444.
18. Sacerdote AS. Modification of expression of non-classical congenital adrenal hyperplasia by pioglitazone. Abstract presented at: 86th Annual Meeting of The Endocrine Society; June 16-19, 2004; New Orleans, LA. Abstract 569.
19. Lutfallah C, Wang W, Mason JI, et al. Newly proposed hormonal criteria via genotypic proof for type II 3beta-hydroxysteroid dehydrogenase deficiency. J Clin Endocrinol Metab. 2002;87:2611-2622.
20. Carbunaru G, Prasad P, Scoccia B, et al. The hormonal phenotype of nonclassic 3 beta-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency. J Clin Endocrinol Metab. 2004;89:783-794.
21. Inoue A, Sawata SY, Taira K. Molecular design and delivery of siRNA. J Drug Target. 2006;14:448-455.
22. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab. 2002;87:1555-1559.
23. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20:535-582.
24. Taylor SI, Dons RF, Hernandez E, Roth J, Gorden P. Insulin resistance associated with androgen excess in women with autoantibodies to the insulin receptor. Ann Intern Med. 1982;97:851-855.
25. Barbieri RL, Smith S, Ryan KJ. The role of hyperinsulinemia in the pathogenesis of ovarian hyperandrogenism. Fertil Steril. 1988;50:197-212.
26. Wang M, Tafuri S. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis. J Cell Biochem. 2003;89:38-47.
27. Seto-Young D, Paliou M, Schlosser J, et al. Direct thiazolidinedione action in the human ovary: insulin-independent and insulin-sensitizing effects on steroidogenesis and insulin-like growth factor binding protein-1 production. J Clin Endocrinol Metab. 2005;90:6099-6105.
28. Kelly SN, McKenna TJ, Young LS. Modulation of steroidogenic enzymes by orphan nuclear transcriptional regulation may control diverse production of cortisol and androgens in the human adrenal. J Endocrinol. 2004;181: 355-365.
29. Pijl H, Ohashi S, Matsuda M. Bromocriptine: a novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000;23:1154-1161.
30. Lombertie ER, Durelle G, Fuseau A. Use and value of the therapeutic neuroleptic-bromocriptine combination in schizophrenia [article in French]. Ann Med Psychol (Paris). 1995;15:531-534.